INTERGROUP TRIAL – CUOG and EORTC
Leading Sponsor: EORTC STUDY 1333-GUCG
Canadian Sponsor: CUOG PEACE 3
EORTC protocol 1333-GUCG
CUOG (Canadian Urological Oncology Group)
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: — aka the “PRIME STUDY”